Loss of serglycin promotes primary tumor growth and vessel functionality in the RIP1-Tag2 mouse model for spontaneous insulinoma formation

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Hamilton, Andrew ^a   Basic, Vladimir ^a   Andersson, Sandra ^a   Abrink, Magnus ^b   Ringvall, Maria ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOGLYCAN; SCATTER FACTOR; SERGLYCIN; UNCLASSIFIED DRUG; VASCULOTROPIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; RALBP1 PROTEIN, MOUSE; VASCULOTROPIN A; VESICULAR TRANSPORT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; INFLAMMATORY CELL; INSULINOMA; INVASIVE CARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TISSUE PERFUSION; TUMOR GROWTH; TUMOR PROMOTION; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; DISEASE COURSE; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGICAL PROCESS; TUMOR CELL LINE;

ANIMALIA; MUS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GTPASE-ACTIVATING PROTEINS; INSULINOMA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PHYSIOLOGICAL PHENOMENA; PROTEOGLYCANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VESICULAR TRANSPORT PROTEINS;

EID: 84929346770     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126688     Document Type: Article

References (25)

1. Kolset SO, Pejler G. Serglycin: a structural and functional chameleon with wide impact on immune cells. J Immunol. 2011; 187(10):4927-33. doi: 10.4049/jimmunol.1100806 PMID: 22049227.
2. Schick BP, Gradowski JF, San Antonio JD. Synthesis, secretion, and subcellular localization of serglycin proteoglycan in human endothelial cells. Blood. 2001; 97(2):449-58. Epub 2001/01/12. PMID: 11154222.
3. He L, Zhou X, Qu C, Tang Y, Zhang Q, Hong J. Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients. Med Oncol. 2013; 30(4):707. Epub 2013/09/03. doi: 10. 1007/s12032-013-0707-4 PMID: 23996242.
4. Korpetinou A, Skandalis SS, Moustakas A, Happonen KE, Tveit H, Prydz K, et al. Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells. PLoS One. 2013; 8(10):e78157. Epub 2013/11/10. doi: 10.1371/journal.pone.0078157 PONE-D-13-33958 [pii]. PMID: 24205138; PubMed Central PMCID: PMC3815026.
5. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, et al. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011; 71(8):3162-72. Epub 2011/02/04. doi: 10.1158/0008-5472.CAN-10-3557 0008-5472.CAN-10-3557 [pii]. PMID: 21289131.
6. Angerth T, Huang RY, Aveskogh M, Pettersson I, Kjellen L, Hellman L. Cloning and structural analysis of a gene encoding a mouse mastocytoma proteoglycan core protein; analysis of its evolutionary relation to three cross hybridizing regions in the mouse genome. Gene. 1990; 93(2):235-40. Epub 1990/ 09/14. PMID: 2121613.
7. Kolset SO, Tveit H. Serglycin-structure and biology. Cell Mol Life Sci. 2008; 65(7-8):1073-85. Epub 2007/12/11. doi: 10.1007/s00018-007-7455-6 PMID: 18066495.
8. Niemann CU, Abrink M, Pejler G, Fischer RL, Christensen EI, Knight SD, et al. Neutrophil elastase depends on serglycin proteoglycan for localization in granules. Blood. 2007; 109(10):4478-86. Epub 2007/02/03. blood-2006-02-001719 [pii] doi: 10.1182/blood-2006-02-001719 PMID: 17272511.
9. Grujic M, Braga T, Lukinius A, Eloranta ML, Knight SD, Pejler G, et al. Serglycin-deficient cytotoxic T lymphocytes display defective secretory granule maturation and granzyme B storage. J Biol Chem. 2005; 280(39):33411-8. Epub 2005/07/28. M501708200 [pii] doi: 10.1074/jbc.M501708200 PMID: 16046402.
10. Åbrink M, Grujic M, Pejler G. Serglycin is essential for maturation of mast cell secretory granule. J Biol Chem. 2004; 279(39):40897-905. PMID: 15231821.
11. Sawesi O, Spillmann D, Lunden A, Wernersson S, Abrink M. Serglycin-independent release of active mast cell proteases in response to Toxoplasma gondii infection. J Biol Chem. 2010; 285(49):38005-13. Epub 2010/09/25. doi: 10.1074/jbc.M110.118471 M110.118471 [pii]. PMID: 20864536; PubMed Central PMCID: PMC2992234.
12. Zernichow L, Abrink M, Hallgren J, Grujic M, Pejler G, Kolset SO. Serglycin is the major secreted proteoglycan in macrophages and has a role in the regulation of macrophage tumor necrosis factor-alpha secretion in response to lipopolysaccharide. J Biol Chem. 2006; 281(37):26792-801. Epub 2006/06/M512889200 [pii] doi: 10.1074/jbc.M512889200 PMID: 16807245.
13. Grujic M, Christensen JP, Sorensen MR, Abrink M, Pejler G, Thomsen AR. Delayed contraction of the CD8+ T cell response toward lymphocytic choriomeningitis virus infection in mice lacking serglycin. J Immunol. 2008; 181(2):1043-51. Epub 2008/07/09. 181/2/1043 [pii]. PMID: 18606656.
14. Theocharis AD, Seidel C, BorsetM, Dobra K, Baykov V, Labropoulou V, et al. Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bonemineralization in vitro. J Biol Chem. 2006; 281(46):35116-28. Epub 2006/07/28. M601061200 [pii] doi: 10.1074/jbc.M601061200 PMID: 16870619.
15. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407(6801):249-57. Epub 2000/09/23. doi: 10.1038/35025220 PMID: 11001068.
16. Purushothaman A, Toole BP. Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth and vascularization. J Biol Chem. 2014. Epub 2014/01/10. doi: 10.1074/jbc.M113.532143 PMID: 24403068.
17. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 1985; 315(6015):115-22. PMID: 2986015.
18. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer. 1998; 77(1):1-10. Epub 1998/02/12. PMID: 9459138; PubMed Central PMCID: PMC2151254.
19. Niemann CU, Cowland JB, Ralfkiaer E, Abrink M, Pejler G, Borregaard N. Serglycin proteoglycan is not implicated in localizing exocrine pancreas enzymes to zymogen granules. Eur J Cell Biol. 2009; 88 (8):473-9. doi: 10.1016/j.ejcb.2009.03.002 PMID: 19446360.
20. Fagiani E, Lorentz P, Kopfstein L, Christofori G. Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. Cancer Res. 2011; 71(17):5717-27. doi: 10. 1158/0008-5472.CAN-10-4635 PMID: 21778249.
21. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Muller KH, Sharkey AM, et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest. 1996; 98(2):482-9. doi: 10.1172/JCI118815 PMID: 8755660; PubMed Central PMCID: PMC507453.
22. McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Archives of surgery. 1999; 134(12):1325-31; discussion 31-2. PMID: 10593330.
23. D'Angelo F, Bernasconi E, Schafer M, Moyat M, Michetti P, Maillard MH, et al. Macrophages promote epithelial repair through hepatocyte growth factor secretion. Clinical and experimental immunology. 2013; 174(1):60-72. doi: 10.1111/cei.12157 PMID: 23773083; PubMed Central PMCID: PMC3784214.
24. McCourt M, Wang JH, Sookhai S, Redmond HP. Activated human neutrophils release hepatocyte growth factor/scatter factor. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2001; 27(4):396-403. doi: 10. 1053/ejso.2001.1133 PMID: 11417987.
25. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annual review of pathology. 2006; 1:119-50. doi: 10.1146/annurev.pathol.1.110304.100224 PMID: 18039110.